{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:54:12Z","timestamp":1792641252879,"version":"4.5.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.toxlet.2020.09.004","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T11:25:39Z","timestamp":1599564339000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Considerations in developing medical countermeasures against chemical ocular toxicity"],"prefix":"10.1016","volume":"334","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-0170","authenticated-orcid":false,"given":"David T.","family":"Yeung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houmam","family":"Araj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill R.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Gennady E.","family":"Platoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2020.09.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.9.12.3","article-title":"Ocular surface - merging challenges and opportunities","author":"Araj","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"6382","key":"10.1016\/j.toxlet.2020.09.004_bib0010","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.aat5956","article-title":"Lumping and splitting","volume":"359","author":"Berg","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.toxlet.2020.09.004_bib0015","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/ICO.0000000000001234","article-title":"Ocular surface changes after sulfur mustard exposure in rabbits, monitored by impression cytology","volume":"36","author":"Dachir","year":"2017","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.toxlet.2020.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1167\/iovs.15-17269","article-title":"ADAM17 inhibitors attenuate corneal epithelial detachment induced by mustard exposure","volume":"57","author":"DeSantis-Rodrigues","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.toxlet.2020.09.004_bib0025","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1167\/iovs.18-24568","article-title":"An engineered human fibroblast growth factor-1 derivative, TTHX1114, ameliorates short-term corneal nitrogen mustard injury in rabbit organ cultures","volume":"59","author":"Eveleth","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.toxlet.2020.09.004_bib0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13181-012-0244-0","article-title":"Medical mitigation model: quantifying the benefits of the public health response to a chemical terrorism attack","volume":"9","author":"Good","year":"2013","journal-title":"J. Med. Toxicol."},{"issue":"1","key":"10.1016\/j.toxlet.2020.09.004_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/nyas.13121","article-title":"Corneal toxicity induced by vesicating agents and effective treatment options","volume":"1374","author":"Goswami","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.toxlet.2020.09.004_bib0040","doi-asserted-by":"crossref","first-page":"104557","DOI":"10.1016\/j.nbd.2019.104557","article-title":"Preface: discovery and development of better medical countermeasures for chemical threats targeting the nervous system","volume":"133","author":"Jett","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.toxlet.2020.09.004_bib0045","doi-asserted-by":"crossref","first-page":"e42837","DOI":"10.1371\/journal.pone.0042837","article-title":"Architectural and biochemical expressions of mustard gas keratopathy: preclinical indicators and pathogenic mechanisms","volume":"7","author":"McNutt","year":"2012","journal-title":"PLoS One"},{"issue":"77","key":"10.1016\/j.toxlet.2020.09.004_bib0050","first-page":"20117","article-title":"\"Office of the Assistant Secretary for Preparedness and Response; HHS Public Health Emergency Medical Countermeasures Enterprise implementation plan for chemical, biological, radiological and nuclear threats. Notice\"","volume":"72","author":"Office of the Assistant Secretary for Preparedness and Response","year":"2007","journal-title":"Fed. Regist."},{"issue":"1","key":"10.1016\/j.toxlet.2020.09.004_bib0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.taap.2012.07.014","article-title":"Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries","volume":"264","author":"Tewari-Singh","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.toxlet.2020.09.004_bib0060","series-title":"The NIH Medical Research Program Directed Against Chemical Threats: 2017 Report on Research Progress and Future Directions","author":"U.S. Department of Health and Human Services","year":"2018"},{"key":"10.1016\/j.toxlet.2020.09.004_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxlet.2020.05.026","article-title":"Abstracts of presentations from the 2020 trans-agency scientific meeting on developing medical countermeasures to treat the acute and chronic effects of ocular chemical toxicity, 25\u201326 February, Bethesda, Maryland","author":"Yeung","year":"2020","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.toxlet.2020.09.004_bib0070","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13181-019-00750-x","article-title":"National Institutes of Health (NIH) executive meeting summary: developing medical countermeasures to rescue opioid-induced respiratory depression (a trans-agency scientific meeting)-August 6\/7, 2019","volume":"16","author":"Yeung","year":"2020","journal-title":"J. Med. Toxicol."},{"issue":"4","key":"10.1016\/j.toxlet.2020.09.004_bib0075","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/acs.chemrestox.0c00086","article-title":"Supporting fundamental chemical toxicology research to inform medical countermeasure developments: the national institutes of health chemical countermeasures research program","volume":"33","author":"Yeung","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.toxlet.2020.09.004_bib0080","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.21707","article-title":"The national institutes of health chemical countermeasures research program (NIH CCRP): a collaborative opportunity to develop effective and accessible chemical medical countermeasures for the American people","author":"Yeung","year":"2020","journal-title":"Drug Dev. Res."}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427420304148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427420304148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:19:17Z","timestamp":1759900757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427420304148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":16,"alternative-id":["S0378427420304148"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2020.09.004","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations in developing medical countermeasures against chemical ocular toxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2020.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}